Chlamydia Trachomatis (CT) and Neisseria Gonorrhoeae (NG) Testing Market Report 2025

This report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market size has grown rapidly in recent years. It will grow from $1.98 billion in 2024 to $2.2 billion in 2025 at a compound annual growth rate (CAGR) of 11.1%. The growth in the historic period can be attributed to emergence of antibiotic resistance, awareness campaigns and education, policy changes.

The chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market size is expected to see rapid growth in the next few years. It will grow to $3.33 billion in 2029 at a compound annual growth rate (CAGR) of 10.9%. The growth in the forecast period can be attributed to telemedicine and telehealth, personalized medicine approaches, point-of-care testing expansion, population health management strategies. Major trends in the forecast period include expansion of rapid point-of-care testing, personalized testing approaches, multi-disease testing platforms, community-based testing and outreach programs.

The escalating prevalence of sexually transmitted infections (STIs) is anticipated to drive the expansion of the chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market in the foreseeable future. STIs, resulting from bacterial, viral, or parasitic infections transmitted through sexual contact, are on the rise due to factors such as inadequate sex education, heightened sexual activity, societal stigma, and accessibility barriers. CT and NG testing plays a crucial role in the detection and management of STIs, facilitating early diagnosis, treatment, and prevention of transmission. For instance, as reported by the World Health Organization in July 2023, over 1 million new STIs are contracted daily worldwide, with an estimated 374 million new infections occurring annually, encompassing one in four treatable STIs. Consequently, the escalating prevalence of sexually transmitted infections underscores the growth trajectory of the CTNG testing market.

Key players in the chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market are prioritizing the development of innovative testing solutions to address the growing need for accurate and scalable testing methods to combat STIs. One such solution is the BD COR MX/PX System, a high-throughput infectious disease molecular diagnostic platform. This sophisticated laboratory instrument is designed to rapidly analyze large numbers of samples for infectious agents. Launched by Becton Dickinson and Company in May 2022, the BD COR MX/PX System streamlines workflow in labs processing numerous infectious disease tests, including CT and NG testing. The platform automates the entire testing process using robotics and software algorithms, enhancing efficiency and potentially reducing wait times for test results. Notable features include automation, high-throughput capability, dual DNA targets, and a modular and scalable design.

In December 2023, Imaware, a US-based health testing company, acquired the consumer testing business from Binx Health for an undisclosed amount. This acquisition enables Imaware to expand its consumer diagnostics portfolio, increasing access to STI screenings and other health tests. Binx Health is a US-based company specializing in at-home and point-of-care diagnostic testing solutions, with a focus on sexual health.

Major companies operating in the chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific, Abbott Laboratories, Danaher Corporation, Merck KGaA, Siemens Healthineers, Becton Dickinson and Company, Grifols SA, Hologic Inc., PerkinElmer, bioMérieux, Sysmex Corporation, Bio-Rad Laboratories, QIAGEN, Quidel Corporation, DiaSorin, Cepheid, Seegene Inc., Meridian Bioscience Inc., Sekisui Diagnostics, J. Mitra & Co. Pvt. Ltd., Atlas Medical, Hardy Diagnostics, Molbio Diagnostics Pvt. Ltd., NG Biotech.

North America was the largest region in the chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market in 2024. The regions covered in the chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market includes revenues earned by entities by providing services such as diagnostic testing, sample collection, laboratory analysis, and confidential counseling. The market value includes the value of related goods sold by the service provider or included within the service offering. The chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market also includes the sale of sample collection kits, control materials, laboratory equipment, and software solutions. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) testing involves diagnosing sexually transmitted infections (STIs) caused by these bacteria in sexually active individuals, particularly those with multiple partners or engaging in unprotected sexual activity. These tests aim to identify the presence of CT and NG bacteria through various methods such as urine samples, genital area swabs, or blood tests.

The primary testing methods for Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) are laboratory testing and point-of-care testing. Laboratories are specialized facilities equipped with trained personnel and specialized equipment to conduct CT and NG testing on patient samples. This includes a range of products such as assays, kits, instruments, and analyzers utilizing various technologies such as isothermal nucleic acid amplification technology, polymerase chain reaction, immunodiagnostics, among others. End users of these laboratory services include diagnostic laboratories, hospitals, clinics, and other healthcare facilities.

The chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market research report is one of a series of new reports that provides chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market statistics, including chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing industry global market size, regional shares, competitors with a chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market share, detailed chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market segments, market trends and opportunities, and any further data you may need to thrive in the chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing industry. This chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.